A Novel Ferroptosis-related Lncrna Prognostic Signature for Colorectal Cancer by Bioinformatics Analysis

Zhiyong Yang
Huanggang Central Hospital Affiliated to Yangtze University

Yujiao Zhang
Huanggang Central Hospital Affiliated to Yangtze University

Jiping Wang
Huanggang Central Hospital Affiliated to Yangtze University

Guodong Yang (✉️ 912391303@qq.com)
Huanggang Central Hospital Affiliated to Yangtze University

Jing Liu
Huanggang Central Hospital Affiliated to Yangtze University

Yaqi Zhang
Huanggang Central Hospital Affiliated to Yangtze University

Research Article

Keywords: LncRNA, TCGA, ferroptosis, colorectal cancer, signature

DOI: https://doi.org/10.21203/rs.3.rs-257325/v1

License: ☑️ ☐ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Recently, extensive studies have shown that ferroptosis in cancer treatment has been increasingly confirmed. The current study aims to construct a robust ferroptosis-related lncRNAs signature prediction model of colorectal cancer (CRC) patients by bioinformatics analysis.

Methods: The transcriptome data were abstracted from The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs were screened by comparing 568 CRC tissues with 44 adjacent non-CRC tissues. Univariate Cox regression, lasso regression, multivariate Cox regression were conducted to design a ferroptosis-related lncRNA signature. This signature's prognosis was verified by the log-rank test of Kaplan-Meier curve and the area under curve (AUC) of receiver operating characteristic (ROC) in train set, test set, and entire set. Furthermore, univariate and multivariate Cox regression were used to analyze its independent prognostic ability. The relationship of the ferroptosis-linked lncRNAs' expression and clinical variables was demonstrated by Wilcoxon rank-sum test and Kruskal-Wallis test. Gene set enrichment analysis (GSEA) was performed to signaling pathways it may involve.

Results: 2541 differentially expressed lncRNAs were screened, of which 439 are ferroptosis-related lncRNAs. A seven ferroptosis-related lncRNAs (AC005550.2, LINC02381, AL137782.1, C2orf27A, AC156455.1, AL354993.2, AC008760.1) prognostic signature was constructed, validated and evaluated. This model's prognosis in the high-risk group is obviously worse than that of the low-risk group in train set, test set, and entire set. The AUC of ROC predicting the three years survival in the train set, test set, and entire set was 0.796, 0.715, and 0.758, respectively. Moreover, the designed molecular signature was found to be an independent prognostic variable. Compared to clinical variables, this signature's ROC curves demonstrated the second largest AUC value (0.737). The expression of these lncRNAs and the lncRNA signature are related to distant metastasis, Lymph-node status, clinical stage, T stage, KRAS mutation, BRAF mutation, MMR status, and perineural invasion. Finally, GSEA analysis results show that the signature is involved in six metabolism-related pathways.

Conclusion: The current study constructed, validated, and evaluated a seven ferroptosis-related lncRNA signature which can independently be used to predict the prognosis of CRC patients, and it may become a new therapeutic target.

Background

In 2018, a total of 1.8 million new patients with colorectal cancer (CRC) and 881,000 CRC-related deaths were reported. This accounted for one in 10 newly diagnosed cases of CRC and CRC-associated deaths. Hence, CRC is ranked as the third most prevalent but second leading cause of cancer-related mortality [1]. Despite the fact that recent advances in the genetic and molecular characterization of tumors, the 5-year survival rate of early CRC exceeds 90% whereas that of rate of metastatic colorectal cancer is below 14% [2]. Therefore, investigating promising prognostic signatures along with potential targets is considered as an essential phase to achieving this goal.
Ferroptosis is a type of cell death that is characterized by high production of lipid ROS (L-ROS) as a result of inactivation of cellular glutathione (GSH)-dependent antioxidant defenses. This form of cell death is iron-dependent and differs from apoptosis, classic necrosis, ferroptosis, and other forms of cell death [3, 4]. Ferroptosis has been associated with the initiation of multiple diseases, including kidney injury, blood circulation diseases, conditions of the nervous system, and ischemia-reperfusion injury. It is therefore being investigated as a potential prognostic marker for various diseases [5]. Scholars have suggested that ferroptosis may be adaptive strategy used for eliminating cancerous cells and hence prevent cancer development in situations of infections, cellular stress, and nutrient deficiency [6]. Previous research has reported that some inducers, such as RSL3 [7], β-elemene [8], Resibufogenin [9], andrographis [10], bromelain [11], IMCA [12], talaroconvolutin A (TalaA) [13], ACADSB [14], erastin [15], dichloroacetate [16], and B. etnensis Raf. extract [17] suppressed the progression of CRC via inducing ferroptosis. Hence, it is essential to discover ferroptosis-linked biomarkers that can be applied as valuable early diagnostic as well as prognostic indicators for CRC.

Long non-coding RNAs (lncRNAs) is a class of non-coding RNAs with more than 200 nucleotides long that have apparently little or no protein-coding ability [18]. LncRNAs regulate critical biological functions related to growth of cells and survival, allosteric regulation of enzyme activities, chromatin modifications, and genomic imprinting [19]. Besides, a mounting number of studies have chronicled that lncRNAs affect cancer progression and predict dismal prognosis in diverse cancer types by modulating ferroptosis. For example, p53 related lncRNA (P53RRA) promotes apoptosis and ferroptosis of cancerous cells by activating the p53 pathway [20]. LncRNA GABPB1-AS1 regulates the status of oxidative stress in context of erastin-triggered ferroptosis in HepG2 hepatocellular carcinoma cells [21]. LncRNA-linc00336 suppresses ferroptosis in lung cancer tissues by acting as a competing endogenous RNA [22]. Linc00618 accelerates ferroptosis via inhibiting vincristine (VCR) and lymphoid-specific helicase (LSH) /SLC7A11 in leukemia [23]. In non-small cell lung cancer cells, LncRNA-MT1DP enriched on folate-modified liposomes promotes erastin-triggered ferroptosis by modulating the miR-365a-3p/NRF2 axis [24]. Hence, it is critical to explore the pivotal lncRNAs closely linked to ferroptosis along with prognosis in CRC.

This study is the first to propose a predictive model of lncRNA related to ferroptosis genes in tumors. Therefore, we postulated that ferroptosis-linked lncRNAs could be valuable prognostic biomarkers for CRC patients. Herein, we explored the expression of lncRNAs in CRC from The Cancer Genome Atlas (TCGA) and identified ferroptosis-associated lncRNAs with prognostic potential. We constructed and verified a seven ferroptosis-correlated lncRNA biosignature with the ability to estimate the survival prognosis of CRC patients.

**Methods**

**Data download and processing**

The transcriptome data (Cases (544): Primary Site (colon and rectum), Program (TCGA), Project (TCGA-COAD and TCGA-READ); Files (612 including 568 CRC tissues and 44 non-CRC tissues): Data Category...
(Transcriptome Profiling), Workflow Type (HTSeq - FPKM)), Data Type (Gene Expression Quantification), clinical information (Files (548), Data Category (clinical), and Data Format (bcr xml)) were abstracted from The Cancer Genome Atlas (TCGA) web data resource (https://cancergenome.nih.gov/) on November 20, 2020 (Table 1). Patients with no follow-up time and follow-up time shorter than 30 days were not enrolled in the study.

**Identification of ferroptosis-associated lncRNAs (FRlncRNAs)**

The ferroptosis genes (259) were downloaded from the world’s first database (ferroptosis regulators and markers and ferroptosis-disease associations (FerrDb)) (http://www.zhounan.org/ferrdb/). We employed the “limma” R package [25] to screen differentially expressed lncRNAs by comparing 568 CRC tissues with 44 adjacent non-CRC tissues. The included criteria are False Discovery Rate (FDR) < 0.05 and |logFC|>1. Furthermore, we identified ferroptosis-related lncRNAs by the correlation analysis between the lncRNAs expression levels and the ferroptosis genes based on the criteria of P < 0.001 and |Correlation Coefficient| > 0.3.

**Development, verification, and assessment of prognostic biosignature**

We utilized the R language 4.0.1 version "caret" package to randomly classify the entire data set (Additional file 1) with FRlncRNAs expression profiles into two sets (train set (Additional file 2) and test set (Additional file 3)), and conducted univariate Cox regression for FRlncRNAs in the train group (P < 0.05). Lasso regression analysis was utilized to minimize overfitting using the "glmnet" package [26] (P < 0.05). Afterward, multivariate Cox regression was employed to develop the optimal prognostic risk model and leveraged "coxph" and "direction = both" functions of the R language "survival" package [27] (P < 0.05). Then, the prognostic lncRNA signature's risk score constituting multiple lncRNAs was developed by summing up the product of each lncRNA with its corresponding coefficient. Additionally, the Proportional Hazards Assumption was tested in the Cox model. Similarly, on the basis of the previous training set's risk score formula, we applied it to the testing set as well as the entire set as validation.

This model was employed to explore each patient's survival prognosis by the Kaplan-Meier curve along with the log-rank test on the basis of the median of risk score, namely low-risk group and high-risk group in the train set, test set, entire set. The lncRNA signature's predictive power was explored by computing the AUC of 3 years using the ROC curve by the "survival ROC" package [28].

To further enhance the prognostic signature's credibility, we conducted a stratified survival prognostic analysis on gender, age, clinical stage, postoperative tumor status, CEA levels, perineural invasion, vascular invasion, mismatch repair (MMR) and gene mutation status (KRAS, BRAF).

**Independent and prognostic value of the lncRNA signature**
Multivariate Cox regression and univariate Cox regression analyses were conducted to analyze the independent and prognostic ability of the IncRNA signature in the train set (Additional file 4), test set (Additional file 5), and entire set (Additional file 6). The clinical parameters include age, gender, clinical stage, T stage, lymph nodes as well as distant metastasis. Besides, compared with clinical variables, The ROC curve was employed to explore whether the IncRNA biosignature has better predictive power. The "rms" package was employed to construct the nomogram according to the multivariate Cox regression result (P < 0.05). To further investigate whether the ferroptosis-associated IncRNAs are involved in CRC development, we explored the relationship of the ferroptosis-linked IncRNAs’ expression with clinical variables using the Wilcoxon rank-sum test and Kruskal-Wallis test.

**GSEA analysis of the IncRNA signature.**

Gene set enrichment analysis (GSEA4.1.0) downloaded from https://www.gsea-msigdb.org/gsea/index.jsp website was employed to identify the biological function of the prediction model [29]. Based on the median expression of IncRNA signature riskScore in 568 tumor samples, we divided them into low and high-risk groups for KEGG analysis of GSEA. The abundant signaling cascades in each phenotype were based on the normalized enrichment score (NES), the nominal (NOM) P-value as well as the false discovery rate (FDR). FDR < 25% and NOM P-value < 5% serve as a standard for inclusion.

**2.6 | Statistical Analysis**

R software 4.0.3 version and attached packages were employed to conduct data analyses. All the statistical analyses were two-sided. P < 0.05 signified of statistical significance.

**Results**

**Screening of ferroptosis-related IncRNAs in CRC**

Comparing CRC tissues with adjacent non-CRC tissues, 2541 differentially expressed IncRNAs were found, of which 1805 are up-regulated and 736 are down-regulated (Additional file 7). The correlation results between 259 ferroptosis-related genes and differentially expressed IncRNAs shown that there are 439 ferroptosis-related IncRNAs (FRlncRNAs) (Additional file 8).

**Construction, validation, and evaluation of a seven ferroptosis-related IncRNAs prognostic signature**

The entire set (N = 506) with 439 FRlncRNAs expression data was randomized into the test set (N = 252) and train set (N = 254). In the univariate Cox regression assessment, 22 FRlncRNAs modulated the overall survival of the patients in the train set (Fig. 1a). Lasso regression was used for further analysis to eliminate overfitting IncRNAs, and the 16 IncRNAs we obtained were used for the subsequent multivariate Cox regression analysis (Fig. 1b-d) (concordance index [C-index], 0.75). The ferroptosis-associated IncRNA prognostic biosignature was developed based by summing up the product of each IncRNA
expression with its corresponding coefficient in multivariate Cox regression as indicated below: IncRNA biosignature risk score= (0.136× expression of AC005550.2) + (0.240× expression of LINC02381) + (-1.407× expression of AL137782.1) + (0.365× expression of C2orf27A) + (0.235× expression of AC156455.1) + (0.280× expression of AL354993.2) + (0.653× expression of AC008760.1). Analysis using the Proportional Hazards Assumption in the Cox model revealed that all the P values > 0.05, implying they conformed to the PH test (Additional file 9).

According to the median value of the risk score, results of the Kaplan-Meier curves demonstrate that the high-risk group has a remarkably dismal overall survival (OS) in contrast with the low-risk group in the train set (P = 2.899E-06), test set (P = 5.314E-03), and entire set (P = 1.1E-06) (Fig. 2a-c). The train set shows three years’ OS for patients with high and low-risk group were 60.6% and 90.5%, respectively. The test set is 63.9% and 90.1%, respectively. The entire set is 60.6% and 90.5%, respectively. The AUC of three years dependent ROC for the seven-IncRNA biosignature achieves 0.796, 0.715, and 0.758 respectively in the train set, test set, and entire set (Fig. 2d-f), which demonstrate the good performance of the model in estimating the CRC patients' OS. The mortality rate was higher in patients with high-risk scores relative to those with low-risk scores in the three sets (Fig. 2g-i). The six lncRNAs' (AC005550.2, LINC02381, C2orf27A, AC156455.1, AL354993.2, AC008760.1) expression of signature were lower in low-risk group compared to the high-risk group in cluster heat map, AL137782.1 oppositely (Fig. 2j-l).

It is worth noting that AC156455.1, and AL354993.2's high expression of this lncRNA signature also has a worse OS than low (Fig. 3). The association of the seven lncRNAs with ferroptosis genes is shown in Fig. 4. In addition, we stratified according to various clinical factors (clinical stage, gender, age, CEA levels, MMR status, postoperative tumor status, perineural invasion, vascular invasion, KRAS mutation, BRAF mutation) and applied the prognostic model to OS detection, which is shown in Fig. 5, the results shown that the signature has good predictive significance for CRC patients in most stratification factors, and part of results are not satisfactory (P > 0.05), which might be due to there are not enough samples in these stratification.

Independent prognostic analysis of the seven ferroptosis-associated lncRNAs signature and its correlation with clinical variables.

The Univariate Cox regression assessment demonstrated that the lncRNA biosignature risk score was evidently correlated with the patients’ OS (hazard ratio HR = 1.224, confidence interval 95% CI = 1.149–1.303, P = 3.69E-10) in train set, (HR = 1.160, 95% CI = 1.016–1.325, P = 0.028) test set, and (HR = 1.179, 95% CI = 1.125–1.235, P = 7.04E-12) entire set (Table 2). Moreover, the multivariate Cox regression analysis demonstrated that the lncRNA biosignature risk score remained independent with OS considering other conventional clinical factors including Lymph-node status, the clinical stage, distant metastasis, and T stage (HR = 1.187, 95% CI = 1.107–1.273, P = 1.39E-06) in the train set, and (HR = 1.122, 95% CI = 1.067–1.180, P = 8.33E-06) in entire set, in spite of P > 0.05 (HR = 1.059, 95% CI = 0.995–1.289, P = 0.059) in test set. Meanwhile, T stage and age were demonstrated as an independent prognostic index.
Compared to clinical variables, this signature risk score's ROC curves of three years demonstrate the second-largest AUC value (0.737) (Fig. 6).

Based on the stratification of clinical variables, the correlation between the IncRNAs and clinical variables shows that LINC02381' expression is related to T stage, Lymph-node status, and clinical stage, KRAS mutation, BRAF mutation, and perineural invasion. C2orf27A' expression is associated with T stage, Lymph-node status, clinical stage, KRAS mutation, MMR. AC156455.1' expression is correlated to Lymph-node status. AL354993.2' expression is connected to distant metastasis, Lymph-node status, clinical stage, KRAS mutation. AC008760.1' expression is concerning to Lymph-node status, distant metastasis, clinical stage, KRAS mutation. AL354993.2' expression is linked to KRAS mutation. The IncRNA signature' risk score is coupled to T stage, Lymph-node status, distant metastasis, clinical stage, and KRAS mutation. (Fig. 7).

**Functional enrichment analysis of the seven ferroptosis-related IncRNAs signature.**

GSEA analysis is used to discover potential biological functions of the seven ferroptosis-associated IncRNAs signature of CRC (Fig. 8). The results showed that three signaling pathways (KEGG_HEDGEHOG_SIGNALING_PATHWAY, KEGG_ARACHIDONIC_ACID_METABOLISM, KEGG_ALPHA_LINOLENIC_ACID_METABOLISM) are obviously enriched in the high-risk group, and three signaling cascades (KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM, KEGG_PENTOSE_PHOSPHATE_PATHWAY KEGG_CITRATE_CYCLE_TCA_CYCLE) were abundant in the low-risk group by c2.cp.kegg.v7.2.symbols.gmt. These results suggest that this signature model may influence CRC progression and prognosis mainly through metabolism-related pathways.

**Discussion**

CRC is a common and aggressive cancer with poor survival and prognosis, mainly due to the prone to metastasis to the liver and lung [30]. Given that there are no accurate and sensitive markers to predict the prognosis of CRC patients, it is crucial to investigate and develop more specific biomarkers to improve the survival of patients. Although the current treatment methods have made great advancements, the prognosis is still very poor. Ferroptosis differs from other types of cell death in terms of biochemically and morphologically and has been shown to regulate cancer development [3]. More and more reports have documented that IncRNA plays a very important role in regulating gene expression and regulation in tumor [19, 31]. In addition, many IncRNAs influence the progression of CRC by regulating ferroptosis. However, there are no reports on that prognostic model of IncRNA related to ferroptosis was constructed. Although two previous genetic prognostic models of ferroptosis have been reported in hepatocellular carcinoma [32] and glioma [33], our study is the first to report the study of ferroptosis-related IncRNA prognostic models in CRC.

In the present study, we downloaded ferroptosis genes from FerrDb, and used the R language and its attached packages to find differentially expressed IncRNAs related to ferroptosis (FRIncRNAs). We randomly grouped all the patients into train set as well as the test set, then a seven ferroptosis-related
IncRNAs signature model (AC005550.2, LINC02381, AL137782.1, C2orf27A, AC156455.1, AL354993.2, AC008760.1) was established through univariate Cox regression, Lasso regression, as well as multivariate Cox regression in the train set. At the same time, the biosignature was verified in the test set as well as the entire set. On the basis of the median risk score, the Kaplan-Meier curves revealed that the high-risk group had an evidently dismal overall survival relative to the low-risk group in the three data sets and various clinical stratification factors. Assessment of the biosignature for OS in the three sets by ROC curve exhibited well predictive value. The Univariate Cox regression as well as the multivariate Cox regression analyses demonstrated that the biosignature had independent prognostic ability considering other conventional clinical variables for CRC patients. On the basis of the multivariate Cox regression results, we developed the nomogram of the clinical prediction model. Furthermore, the seven IncRNAs and the signature model are linked to the T stage, Lymph-node status, distant metastasis, clinical stage, KRAS mutation, BRAF mutation, and perineural invasion to varying degrees. Finally, GSEA analysis results show that the signature model is involved in six KEGG signal pathways based on high and low-risk group, such as KEGG_HEDGEHOG_SIGNALING_PATHWAY, KEGG_ARACHIDONIC_ACID_METABOLISM, KEGG_ALPHA_LINOLENIC_ACID_METABOLISM, KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM, KEGG_PENTOSE_PHOSPHATE_PATHWAY, and KEGG_CITRATE_CYCLE_TCA_CYCLE. These results suggest that this signature model may influence CRC progression and prognosis mainly through metabolism-related pathways.

Before this study, many prognostic models of CRC have been constructed from different research perspectives. For example, using bioinformatics tool, Yang G et al. identified a five-microRNA signature which could predict the prognosis of CRC [34]. Bai J et al. developed a novel 14-gene immune-related signature which showed good performance in prognosis prediction of CRC [35]. Zhang J et al. screened gene signature of prognostic m6A modulators in CRC [36]. Using immune and inflammatory cells, Xiao G et al. constructed a risk signature for assessing efficiency of chemotherapy and distant metastases of CRC [37]. Tokunaga R et al. presented a 12-chemokine signature for evaluating tumor recurrence in CRC [38]. Zong Z et al. demonstrated a prognostic alternative splicing signature by differential splicing patterns of 13 genes in CRC [39]. Li K et al. revealed a six gene-specific DNA methylation signature for CRC [40]. Zhou Z et al. developed and validated of an autophagy signature based on 5 autophagy genes which could evaluate the survival of CRC patients after surgery [41]. Wu B et al. developed an immune infiltration-related eight-gene prognostic signature in CRC microenvironment [42]. These examples are only the tip of the iceberg. At present, there are no reports about the prognostic model of IncRNA related to ferroptosis in tumors.

Among these IncRNAs of the signature, some studies have shown that LINC02381 is related to immune gene [43] and autophagy gene [44] in colon adenocarcinoma. Interestingly, our research shows that this IncRNA is also related to ferroptosis, which is worthy of our in-depth thinking. In addition, Jafarzadeh, M et al’ study revealed that LINC02381 might suppress human CRC tumorigenesis partly by regulating PI3K signaling pathway [45]. Meanwhile, LINC02381 inhibits gastric cancer progression and metastasis through regulating wnt signaling pathway [46]. However, LINC02381 functions as a cancer-promoting gene to promote cell migration and viability by regulating mir-133b / RhoA in cervical cancer [47].
AC008760.1 was reported to be related to autophagy, and Li et al. constructed an autophagy-related lncRNA prognosis model in CRC [48]. The remaining lncRNAs have not seen relevant reports in previous studies, which are worthy of further research.

Our study found that the expression of these lncRNAs and the constructed prognostic signature were closely related to the patient's clinical stage, distant metastasis, Lymph-node status, T stage, MMR status, BRAF mutation, KRAS mutation, and perineural invasion, especially the MMR status, BRAF mutation and KRAS mutation. These features have an important guiding significance for patients' medication. So can we explore whether these lncRNAs regulate these variables and how to regulate them? There have been many studies about ferroptosis in the drug resistance of tumor patients [49, 50]. The current study demonstrated the prognostic significance of these ferroptosis-related lncRNAs and signature in CRC. Therefore, we have reason to believe that these lncRNAs are worthy of in-depth research in tumor resistance mechanisms.

Our current study also has some limitations. First, we use the data in the TCGA database as the starting point for research; although the model has been internally verified, it is still needed for further verification in external data; second, TCGA's race is mainly white (75%), and whether the model fits other race needs further verification. Third, the analysis of the lncRNA expression of the model and the KEGG function enrichment analysis by the GSEA model requires further cell function experimental analysis.

Conclusion

Herein, we established a novel ferroptosis-related lncRNA prognostic signature model comprising seven lncRNAs (AC005550.2, LINC02381, AL137782.1, C2orf27A, AC156455.1, AL354993.2, AC008760.1) in CRC. In the future, the seven ferroptosis-related lncRNA prognostic biosignature could enhance predictive accuracy as well as guide individualized therapy for CRC patients with prospective validation.

Abbreviations

CRC: Colorectal cancer; GSEA: Gene set enrichment analysis; FDR: False discovery rate; OS: Overall survival; HRs: Hazard ratios; CI: Confidence interval; TCGA: The Cancer Genome Atlas; AUC: Area under curve; ROC: Receiver operating characteristic; KEGG: Kyoto Encyclopedia of Genes and Genomes.

Declarations

Ethics approval and consent to participate

LncRNA and mRNA sequencing profiles were obtained from the TCGA data portal, which is a publicly available dataset. Therefore, no ethics approval is needed.

Consent for publication
Not applicable

**Availability of data and materials**

The transcriptome data (HTSeq - FPKM)) and clinical information were downloaded from The Cancer Genome Atlas (TCGA) ([https://cancergenome.nih.gov/](https://cancergenome.nih.gov/)). The ferroptosis genes were downloaded from Human Ferroptosis Database (HADb) ([http://www.ferroptosis.lu](http://www.ferroptosis.lu)).

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The present study was supported by the Huanggang Municipal General Project of China (grant no. KJS0012).

**Authors’ contributions**

Yujiao Zhang downloaded the lncRNA and mRNA expression information. Zhiyong Yang constructed the lncRNA signature model and performed the statistical analysis using R language software, and wrote the first draft of the manuscript. Jiping Wang revised the manuscript. Guodong Yang and Jing Liu contributed conception and design of the study and checked the manuscript.

**Acknowledgements**

Not applicable.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. *CA Cancer J Clin* 2018, 68(6):394–424.

2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: *Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012*. *Eur J Cancer* 2013, 49(6):1374–1403.

3. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS *et al*: *Ferroptosis: an iron-dependent form of nonapoptotic cell death*. *Cell* 2012, 149(5):1060–1072.

4. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB *et al*: *Regulation of ferroptotic cancer cell death by GPX4*. *Cell* 2014, 156(1–2):317–331.
5. Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B, Wang G: Ferroptosis: past, present and future. *Cell Death Dis* 2020, 11(2):88.

6. Fearnhead HO, Vandenabeele P, Vanden Berghe T: How do we fit ferroptosis in the family of regulated cell death? *Cell Death Differ* 2017, 24(12):1991–1998.

7. Sui X, Zhang R, Liu S, Duan T, Zhai L, Zhang M, Han X, Xiang Y, Huang X, Lin H et al: RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer. *Front Pharmacol* 2018, 9:1371.

8. Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J et al: Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. *Theranostics* 2020, 10(11):5107–5119.

9. Shen LD, Qi WH, Bai JJ, Zuo CY, Bai DL, Gao WD, Zong XL, Hao TT, Ma Y, Cao GC: Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation. *Anat Rec (Hoboken)* 2020.

10. Sharma P, Shimura T, Banwait JK, Goel A: Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of beta-catenin/Wnt-signaling pathways in colorectal cancer. *Carcinogenesis* 2020, 41(10):1385–1394.

11. Park S, Oh J, Kim M, Jin EJ: Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis. *Anim Cells Syst (Seoul)* 2018, 22(5):334–340.

12. Zhang L, Liu W, Liu F, Wang Q, Song M, Yu Q, Tang K, Teng T, Wu D, Wang X et al: IMCA Induces Ferroptosis Mediated by SLC7A11 through the AMPK/mTOR Pathway in Colorectal Cancer. *Oxid Med Cell Longev* 2020, 2020:1675613.

13. Xia Y, Liu S, Li C, Ai Z, Shen W, Ren W, Yang X: Discovery of a novel ferroptosis inducer-talaroconvolutin A-killing colorectal cancer cells in vitro and in vivo. *Cell Death Dis* 2020, 11(11):988.

14. Lu D, Yang Z, Xia Q, Gao S, Sun S, Luo X, Li Z, Zhang X, Li X: ACADSB regulates ferroptosis and affects the migration, invasion, and proliferation of colorectal cancer cells. *Cell Biol Int* 2020, 44(11):2334–2343.

15. Xu X, Zhang X, Wei C, Zheng D, Lu X, Yang Y, Luo A, Zhang K, Duan X, Wang Y: Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis. *Eur J Pharm Sci* 2020, 152:105450.

16. Sun J, Cheng X, Pan S, Wang L, Dou W, Liu J, Shi X: Dichloroacetate attenuates the stemness of colorectal cancer cells via trigerring ferroptosis through sequestering iron in lysosomes. *Environ Toxicol* 2020.

17. Malfa GA, Tomasello B, Acquaviva R, Genovese C, La Mantia A, Cammarata FP, Ragusa M, Renis M, Di Giacomo C: Betula etnensis Raf. (Betulaceae) Extract Induced HO-1 Expression and Ferroptosis Cell Death in Human Colon Cancer Cells. *Int J Mol Sci* 2019, 20(11).

18. Mercer TR, Dinger ME, Mattick JS: Long non-coding RNAs: insights into functions. *Nature reviews Genetics* 2009, 10(3):155–159.
19. Quinn JJ, Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 2016, 17(1):47–62.

20. Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, Shi Y, Shen Y, Liu X, Lai W et al: A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. Cancer Res 2018, 78(13):3484–3496.

21. Qi W, Li Z, Xia L, Dai J, Zhang Q, Wu C, Xu S: LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells. Sci Rep 2019, 9(1):16185.

22. Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, Shi Y, Chen L, Xiao D, Yu F et al: Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ 2019, 26(11):2329–2343.

23. Wang Z, Chen X, Liu N, Shi Y, Liu Y, Ouyang L, Tam S, Xiao D, Liu S, Wen F et al: A Nuclear Long Non-Coding RNA LINC00618 Accelerates Ferroptosis in a Manner Dependent upon Apoptosis. Mol Ther 2020.

24. Gai C, Liu C, Wu X, Yu M, Zheng J, Zhang W, Lv S, Li W: MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells. Cell Death Dis 2020, 11(9):751.

25. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43(7):e47.

26. Simon N, Friedman J, Hastie T, Tibshirani R: Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. J Stat Softw 2011, 39(5):1–13.

27. Groeneveld CS, Chagas VS, Jones SJM, Robertson AG, Ponder BAJ, Meyer KB, Castro MAA: RTNsurvival: an R/Bioconductor package for regulatory network survival analysis. Bioinformatics 2019, 35(21):4488–4489.

28. Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56(2):337–344.

29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102(43):15545–15550.

30. Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A et al: Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015, 41(9):729–741.

31. Bhan A, Soleimani M, Mandal SS: Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res 2017, 77(15):3965–3981.

32. Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y, Li YH: A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci 2020, 16(13):2430–2441.
33. Zhuo S, Chen Z, Yang Y, Zhang J, Tang J, Yang K: Clinical and Biological Significances of a Ferroptosis-Related Gene Signature in Glioma. *Front Oncol* 2020, 10:590861.

34. Yang G, Zhang Y, Yang J: A Five-microRNA Signature as Prognostic Biomarker in Colorectal Cancer by Bioinformatics Analysis. *Front Oncol* 2019, 9:1207.

35. Bai J, Zhang X, Xiang ZX, Zhong PY, Xiong B: Identification of prognostic immune-related signature predicting the overall survival for colorectal cancer. *Eur Rev Med Pharmacol Sci* 2020, 24(3):1134–1141.

36. Zhang J, Cheng X, Wang J, Huang Y, Yuan J, Guo D: Gene signature and prognostic merit of M6a regulators in colorectal cancer. *Exp Biol Med (Maywood)* 2020, 245(15):1344–1354.

37. Hu X, Li YQ, Ma XJ, Zhang L, Cai SJ, Peng JJ: A Risk Signature With Inflammatory and T Immune Cells Infiltration in Colorectal Cancer Predicting Distant Metastases and Efficiency of Chemotherapy. *Front Oncol* 2019, 9:704.

38. Tokunaga R, Nakagawa S, Sakamoto Y, Nakamura K, Naseem M, Izumi D, Kosumi K, Taki K, Higashi T, Miyata T et al.: 12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. *Int J Cancer* 2020, 147(2):532–541.

39. Zong Z, Li H, Yi C, Ying H, Zhu Z, Wang H: Genome-Wide Profiling of Prognostic Alternative Splicing Signature in Colorectal Cancer. *Front Oncol* 2018, 8:537.

40. Li K, Zeng L, Wei H, Hu J, Jiao L, Zhang J, Xiong Y: Identification of gene-specific DNA methylation signature for Colorectal Cancer. *Cancer Genet* 2018, 228–229:5–11.

41. Zhou Z, Mo S, Dai W, Ying Z, Zhang L, Xiang W, Han L, Wang Z, Li Q, Wang R et al.: Development and Validation of an Autophagy Score Signature for the Prediction of Post-operative Survival in Colorectal Cancer. *Front Oncol* 2019, 9:878.

42. Wu B, Tao L, Yang D, Li W, Xu H, He Q: Development of an Immune Infiltration-Related Eight-Gene Prognostic Signature in Colorectal Cancer Microenvironment. *Biomed Res Int* 2020, 2020:2719739.

43. Li Z, Wang D, Yin H: A seven immune-related IncRNA signature predicts the survival of patients with colon adenocarcinoma. *Am J Transl Res* 2020, 12(11):7060–7078.

44. Zhou W, Zhang S, Li HB, Cai Z, Tang S, Chen LX, Lang JY, Chen Z, Chen XL: Development of Prognostic Indicator Based on Autophagy-Related IncRNA Analysis in Colon Adenocarcinoma. *Biomed Res Int* 2020, 2020:9807918.

45. Jafarzadeh M, Soltani BM, Soleimani M, Hosseinkhani S: Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway. *Biochimie* 2020, 171–172:63–71.

46. Jafarzadeh M, Soltani BM: Long Noncoding RNA LOC400043 (LINC02381) Inhibits Gastric Cancer Progression Through Regulating Wnt Signaling Pathway. *Front Oncol* 2020, 10:562253.

47. Chen X, Zhang Z, Ma Y, Su H, Xie P, Ran J: LINC02381 Promoted Cell Viability and Migration via Targeting miR-133b in Cervical Cancer Cells. *Cancer Manag Res* 2020, 12:3971–3979.
48. Wei J, Ge X, Tang Y, Qian Y, Lu W, Jiang K, Fang Y, Hwang M, Fu D, Xiao Q et al: An Autophagy-Related Long Noncoding RNA Signature Contributes to Poor Prognosis in Colorectal Cancer. *J Oncol* 2020, **2020**:4728947.

49. Friedmann Angeli JP, Krysko DV, Conrad M: Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. *Nat Rev Cancer* 2019, **19**(7):405–414.

50. Elgendy SM, Alyammahi SK, Alhamad DW, Abdin SM, Omar HA: Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance. *Crit Rev Oncol Hematol* 2020, **155**:103095.

**Tables**

Due to technical limitations, table 1 and 2 is only available as a download in the Supplemental Files section.